These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

702 related items for PubMed ID: 16426100

  • 1. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.
    Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Earl CQ, Jiang JG, Biederman J.
    J Clin Psychiatry; 2006 Jan; 67(1):137-47. PubMed ID: 16426100
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, Greenhill L.
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [Abstract] [Full Text] [Related]

  • 3. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study.
    Biederman J, Swanson JM, Wigal SB, Boellner SW, Earl CQ, Lopez FA, Modafinil ADHD Study Group.
    J Clin Psychiatry; 2006 May; 67(5):727-35. PubMed ID: 16841622
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder.
    Greenhill LL, Biederman J, Boellner SW, Rugino TA, Sangal RB, Earl CQ, Jiang JG, Swanson JM.
    J Am Acad Child Adolesc Psychiatry; 2006 May; 45(5):503-511. PubMed ID: 16601402
    [Abstract] [Full Text] [Related]

  • 5. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
    Boellner SW, Earl CQ, Arora S.
    Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 7. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
    Biederman J, Pliszka SR.
    J Pediatr; 2008 Mar; 152(3):394-9. PubMed ID: 18280848
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder.
    Kahbazi M, Ghoreishi A, Rahiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S.
    Psychiatry Res; 2009 Aug 15; 168(3):234-7. PubMed ID: 19439364
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: pooled analysis of 3 randomized, double-blind, placebo-controlled studies.
    Wigal SB, Biederman J, Swanson JM, Yang R, Greenhill LL.
    Prim Care Companion J Clin Psychiatry; 2006 Aug 15; 8(6):352-60. PubMed ID: 17245457
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH, Greenbaum M, Arnold V, Yu M, Yan B, Jaffee M, Robertson B.
    CNS Drugs; 2017 Aug 15; 31(8):685-697. PubMed ID: 28712074
    [Abstract] [Full Text] [Related]

  • 11. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S.
    CNS Drugs; 2017 Nov 15; 31(11):999-1014. PubMed ID: 28980198
    [Abstract] [Full Text] [Related]

  • 12. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
    Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Bloomfield R, Squires LA, Coghill DR.
    CNS Drugs; 2013 Sep 15; 27(9):743-51. PubMed ID: 23801529
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB, Nordbrock E, Adjei AL, Childress A, Kupper RJ, Greenhill L.
    CNS Drugs; 2015 Apr 15; 29(4):331-40. PubMed ID: 25877989
    [Abstract] [Full Text] [Related]

  • 14. SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study.
    Brams M, Childress AC, Greenbaum M, Yu M, Yan B, Jaffee M, Robertson B.
    J Child Adolesc Psychopharmacol; 2018 Feb 15; 28(1):19-28. PubMed ID: 28816509
    [Abstract] [Full Text] [Related]

  • 15. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A, Hull JT, Chaturvedi SA, Liranso T, Odebo O, Kosheleff AR, Fry N, Cutler AJ, Rubin J, Schwabe S, Childress A.
    CNS Drugs; 2022 Aug 15; 36(8):897-915. PubMed ID: 35896943
    [Abstract] [Full Text] [Related]

  • 16. Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis.
    Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU.
    J Psychiatr Res; 2017 Jan 15; 84():292-300. PubMed ID: 27810669
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L.
    J Am Acad Child Adolesc Psychiatry; 2011 Apr 15; 50(4):395-405. PubMed ID: 21421179
    [Abstract] [Full Text] [Related]

  • 18. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L.
    Eur Neuropsychopharmacol; 2013 Oct 15; 23(10):1208-18. PubMed ID: 23332456
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
    Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL.
    Clin Ther; 2007 Mar 15; 29(3):450-63. PubMed ID: 17577466
    [Abstract] [Full Text] [Related]

  • 20. A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder.
    Mattingly G, Arnold V, Yan B, Yu M, Robertson B.
    J Child Adolesc Psychopharmacol; 2020 Nov 15; 30(9):549-557. PubMed ID: 33185468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.